France-based biopharmaceutical company Adcytherix has announced its launch with seed funding of €30m ($32.2m) aimed at developing new antibody-drug conjugates (ADCs) for cancer treatment. The company will focus on the development of ADCs targeting diseases with significant unmet medical needs.
The gold standard of business intelligence. The financial injection marks a significant milestone for Adcytherix, which was founded by Jack Elands and Pontifax Venture Capital. Xavier Preville and Carsten Dehning are co-founders.
Jack Elands is CEO, Dehning is chief financial officer and Preville is research and preclinical development vice-president and head. The seed funding round was spearheaded by Pontifax and received support from a consortium of top-tier life science investors, including RA Capital Management, Pureos Bioventures and Dawn Biopharma — a platform under the control of global investment firm . The company’s management team also contributed to the seed funding.
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form Elands stated: “Our new company has as its objective to meet the most urgent need of patients by developing a next ge.